万邦医药
(301520)
| 流通市值：23.57亿 | | | 总市值：67.16亿 |
| 流通股本：3269.84万 | | | 总股本：9317.14万 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 87,757,664.33 | 30,541,322 | 274,180,232.26 | 209,425,876.45 |
| 营业收入 | 87,757,664.33 | 30,541,322 | 274,180,232.26 | 209,425,876.45 |
| 利息收入 | - | 0 | 0 | 0 |
| 已赚保费 | - | 0 | 0 | 0 |
| 手续费及佣金收入 | - | 0 | 0 | 0 |
| 二、营业总成本 | 104,892,117.23 | 40,632,188.33 | 265,143,198.25 | 206,411,326.1 |
| 营业成本 | 71,612,026.83 | 25,885,199.43 | 203,170,661.76 | 145,708,733.9 |
| 利息支出 | - | 0 | 0 | 0 |
| 手续费及佣金支出 | - | 0 | 0 | 0 |
| 退保金 | - | 0 | 0 | 0 |
| 赔付支出净额 | - | 0 | 0 | 0 |
| 提取保险合同准备金净额 | - | 0 | 0 | 0 |
| 保单红利支出 | - | 0 | 0 | 0 |
| 分保费用 | - | 0 | 0 | 0 |
| 税金及附加 | 974,977.07 | 315,300.06 | 1,611,082.66 | 1,250,927.72 |
| 销售费用 | 4,397,757.45 | 1,763,376.35 | 5,822,278.66 | 5,623,066.89 |
| 管理费用 | 12,398,724.97 | 4,723,614.48 | 22,607,587.91 | 17,786,102.5 |
| 研发费用 | 15,754,626.35 | 8,054,159.67 | 32,931,809.85 | 36,961,787.88 |
| 财务费用 | -245,995.44 | -109,461.66 | -1,000,222.59 | -919,292.79 |
| 其中:利息费用 | 0 | 0 | - | 0 |
| 其中:利息收入 | 253,850.52 | 115,137.62 | 1,021,521.88 | 936,587.48 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,703,782.34 | 5,992,624.03 | 18,983,525.97 | 16,310,483.36 |
| 加:投资收益 | 7,933,275.38 | 1,162,395.73 | 12,933,909.07 | 7,945,781.97 |
| 净敞口套期收益 | - | 0 | 0 | 0 |
| 汇兑收益 | - | 0 | 0 | 0 |
| 资产处置收益 | -7,038.83 | 0 | -55,767.7 | 0 |
| 资产减值损失(新) | 617,633.07 | 479,612.05 | -2,340,086.16 | -1,414,335.51 |
| 信用减值损失(新) | -3,646,463.27 | -195,940.71 | -4,788,193.39 | -1,394,314.75 |
| 其他收益 | 1,385,784.83 | 847,941.39 | 7,695,111.98 | 5,968,067.64 |
| 四、营业利润 | -3,147,479.38 | -1,804,233.84 | 41,465,533.78 | 30,430,233.06 |
| 加:营业外收入 | 294.77 | 0 | 7,066.53 | 7,042.37 |
| 减:营业外支出 | 76,482.23 | 1.2 | 5,619,461.89 | 50,023.71 |
| 五、利润总额 | -3,223,666.84 | -1,804,235.04 | 35,853,138.42 | 30,387,251.72 |
| 减:所得税费用 | -3,361,659.71 | -1,542,452.88 | -581,315.15 | -2,723,367.4 |
| 六、净利润 | 137,992.87 | -261,782.16 | 36,434,453.57 | 33,110,619.12 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 137,992.87 | -261,782.16 | 36,434,453.57 | 33,110,619.12 |
| 终止经营净利润 | - | 0 | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 137,992.87 | -261,782.16 | 36,434,453.57 | 33,110,619.12 |
| 少数股东损益 | - | - | - | 0 |
| 扣除非经常损益后的净利润 | -13,430,876.92 | -6,625,378.24 | 8,932,974.8 | 8,449,166.49 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0 | 0 | 0.55 | 0.5 |
| (二)稀释每股收益 | 0 | 0 | 0.55 | 0.5 |
| 八、其他综合收益 | - | - | 0 | 0 |
| 归属于母公司股东的其他综合收益 | - | - | - | 0 |
| 九、综合收益总额 | 137,992.87 | -261,782.16 | 36,434,453.57 | 33,110,619.12 |
| 归属于母公司股东的综合收益总额 | 137,992.87 | -261,782.16 | 36,434,453.57 | 33,110,619.12 |
| 归属于少数股东的综合收益总额 | - | - | - | 0 |
| 公告日期 | 2026-08-29 | 2026-04-23 | 2026-04-23 | 2025-10-23 |
| 审计意见(境内) | | | 标准无保留意见 | |